597 related articles for article (PubMed ID: 30068375)
1. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
[TBL] [Abstract][Full Text] [Related]
2. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.
Yagishita S; Fujita Y; Kitazono S; Ko R; Nakadate Y; Sawada T; Kitamura Y; Shimoyama T; Maeda Y; Takahashi F; Takahashi K; Tamura T; Koizumi F
Mol Cancer Ther; 2015 Jun; 14(6):1414-23. PubMed ID: 25833836
[TBL] [Abstract][Full Text] [Related]
4. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
5. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
[TBL] [Abstract][Full Text] [Related]
6. The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.
Zheng L; Li X; Gu Y; Lv X; Xi T
Breast Cancer Res Treat; 2015 Feb; 150(1):105-18. PubMed ID: 25701119
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic p95HER2 regulates Na+-HCO3- cotransporter NBCn1 mRNA stability in breast cancer cells via 3'UTR-dependent processes.
Gorbatenko A; Olesen CW; Loebl N; Sigurdsson HH; Bianchi C; Pedraz-Cuesta E; Christiansen J; Pedersen SF
Biochem J; 2016 Nov; 473(21):4027-4044. PubMed ID: 27609814
[TBL] [Abstract][Full Text] [Related]
8. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
[TBL] [Abstract][Full Text] [Related]
10. Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.
Zhao Z; Li R; Sha S; Wang Q; Mao W; Liu T
Cancer Biol Ther; 2014 Oct; 15(10):1404-12. PubMed ID: 25046105
[TBL] [Abstract][Full Text] [Related]
11. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
12. Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.
Xu X; Lv YG; Yan CY; Yi J; Ling R
Biochem Biophys Res Commun; 2016 Oct; 479(4):893-900. PubMed ID: 27693788
[TBL] [Abstract][Full Text] [Related]
13. Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.
Li X; Duan Y; Qiao C; Zhou T; Yu M; Geng J; Feng J; Shen B; Lv M; Li Y
Technol Cancer Res Treat; 2016 Aug; 15(4):573-82. PubMed ID: 26041400
[TBL] [Abstract][Full Text] [Related]
14. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL
Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399
[TBL] [Abstract][Full Text] [Related]
15. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Nonagase Y; Yonesaka K; Kawakami H; Watanabe S; Haratani K; Takahama T; Takegawa N; Ueda H; Tanizaki J; Hayashi H; Yoshida T; Takeda M; Chiba Y; Tamura T; Nakagawa K; Tsurutani J
Oncotarget; 2016 Dec; 7(51):84860-84871. PubMed ID: 27768588
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
17. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
[TBL] [Abstract][Full Text] [Related]
18. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
Lipton A; Goodman L; Leitzel K; Cook J; Sperinde J; Haddad M; Köstler WJ; Huang W; Weidler JM; Ali S; Newton A; Fuchs EM; Paquet A; Singer CF; Horvat R; Jin X; Banerjee J; Mukherjee A; Tan Y; Shi Y; Chenna A; Larson J; Lie Y; Sherwood T; Petropoulos CJ; Williams S; Winslow J; Parry G; Bates M
Breast Cancer Res Treat; 2013 Aug; 141(1):43-53. PubMed ID: 23959396
[TBL] [Abstract][Full Text] [Related]
19. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
Baumann J; Wong J; Sun Y; Conklin DS
BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
[TBL] [Abstract][Full Text] [Related]
20. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
Baldassarre T; Truesdell P; Craig AW
Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
